Clear Gene

Clear Gene develops genomic and machine learning solutions to detect residual solid tumor disease, with products aimed at aiding clinical labs and PCR workflows. The focus covers cancer residual disease detection and Covid-related lab tooling, emphasizing compatibility with existing equipment and single-interface software.

The company offers MICA Software, a signal-processing platform that standardizes Ct calls across tests and instruments in a single interface. MICA Test Kits provide rapid, drop-in replacements for PCR, and MICA-Direct Kits supply reagents to bypass RNA isolation, enabling 5-minute extractions compatible with PCR and isothermal tests like MICA.

Who it’s for: Clinical laboratories and diagnostic labs performing cancer residual disease testing and Covid-19 related assays, seeking cost reduction and streamlined workflows on existing equipment.

Hiring/traction mentions not explicit; multiple product lines and ongoing lab workflow integrations suggest active development and commercialization.